USE OF (1R,5S)-(+)-1-(NAPHTHALEN-2-YL)-3-AZABICYCLO[3.1.0]HEXANE IN THE TREATMENT OF CONDITIONS AFFECTED BY MONOAMINE NEUROTRANSMITTERS
The present invention relates to (lR,5S)-(+)-l-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane and pharmaceutical compositions thereof, and methods employing their use in the treatment of conditions affected by monoamine neurotransmitters, including ADHD and substance abuse. La présente invention concer...
Saved in:
Main Authors | , |
---|---|
Format | Patent |
Language | English French |
Published |
18.05.2021
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present invention relates to (lR,5S)-(+)-l-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane and pharmaceutical compositions thereof, and methods employing their use in the treatment of conditions affected by monoamine neurotransmitters, including ADHD and substance abuse.
La présente invention concerne le (lR,5S)-(+)-l-(naphthalèn-2-yl)-3-azabicyclo[3.1.0]hexane et des compositions à base de celui-ci, ainsi que leurs méthodes d'utilisation dans le cadre du traitement d'affections associées aux neurotransmetteurs mono-amine, parmi lesquelles le trouble d'hyperactivité avec déficit de l'attention et l'abus d'alcool ou d'autres drogues. |
---|---|
Bibliography: | Application Number: CA20122843847 |